Updated safety and educational materials are now available to support the implementation of the regulatory measures announced in the November 2023 National Patient Safety Alert and the September 2024 Drug Safety Update. They also include previous updates to product information on the risk of low birth weight in children exposed to valproate during pregnancy.
Similar Posts
Guidance: Updates to CIR 520/2012 – Information for UK Marketing Authorisation Holders
This guidance clarifies the expectations on the application of the further pharmacovigilance provisions set out within the updated CIR 520/2012 for UK authorised products.
Clinical investigations for medical devices
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Medical devices: conformity assessment and the UKCA mark
How to conform with the legal requirements for placing medical devices on the market.
Field safety notices: guidance for manufacturers
How to write clear and effective field safety notices (FSNs) for medical devices.
Good clinical practice for clinical trials
How to show the MHRA you’re meeting good clinical practice (GCP) standards and what to expect from an inspection.
Class 2 Medicines Recall: Baxter Healthcare Limited, Compound Sodium Lactate Solution for Infusion BP (Hartmann’s Solution for infusion) in Viaflo 1000ml, EL(25)A/46
Baxter Healthcare is recalling one batch of Compound Sodium Lactate (Hartmann’s Solution) 1000mL. This is due to a packaging error where some cartons labelled as Hartmann’s Solution may contain Ringer’s Solution 1000mL.